FKBPL and preeclampsia: While CRISPR/Cas9 technology is a powerful gene-editing tool, it has limitations, including the potential for off-target effects and technical challenges in creating stable K/O cell lines, especially for essential genes like Fkbpl. Fkbpl’s role in cell survival, angiogenesis, and cell cycle regulation makes it particularly difficult to generate stable K/O cell lines, despite the potential benefits of such models for studying preeclampsia.